CRD 102 - Cardiora

Drug Profile

CRD 102 - Cardiora

Alternative Names: CRD-102 - Cardiora

Latest Information Update: 23 Jun 2016

Price : $50

At a glance

  • Originator Cardiora
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Heart failure

Most Recent Events

  • 05 Jul 2017 Cardiora plans a phase Ib/IIa trial for Heart failure (In adults, In the elderly, Treatment-experienced) (PO) (NCT03217331)
  • 16 Jun 2016 Preclinical trials in Heart failure in USA (PO) before June 2016 (Cardiora website, June 2016)
  • 16 Jun 2016 Cardiora plans to file an IND application with the US FDA for Heart faliure in the fourth quarter of 2016 (Cardiora website, June 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top